Combinations between Atezolizumab (anti-PD-L1, a PD-1 ligand) with Cabonzantinib, an anti-vascular endothelial growth factor receptor (VEGFR), showed higher efficacy [11] prompted their use as first line treatments in advanced HCC [12]. Here, CD274 is linked to hepatocellular carcinoma.